Clinical Trials Browser

INDUSTRY × Carcinoma × Paclitaxel × Clear all

NCT06312137 2026-05-22

TroFuse-019

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05768932 2026-03-27

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

BreastGastrointestinalOther hematologic neoplasm

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT06693336 2026-03-06

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03976362 2026-02-25

KEYLYNK-008

Phase 3 Completed

851 enrolled 25 charts

Carcinoma

NCT05283226 2026-01-23

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Phase 2 Recruiting

Carcinoma

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase 1/2 Active not recruiting

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT06317311 2025-07-25

RUBY-J

Phase 2 Active not recruiting

Carcinoma, Endometrial Neoplasms

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02915744 2023-04-14

ATTAIN

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT00152477 2022-04-12

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Phase 2 Completed

165 enrolled 16 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00654758 2017-11-21

A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00998192 2016-03-31

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Phase 2 Completed

Carcinoma, Neoplasm Metastasis

NCT00861627 2015-12-02

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Phase 2 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT01253681 2015-10-14

Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

Phase 1 Completed

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01764087 2015-05-18

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Phase 1/2 Unknown

BreastGastrointestinal

Breast Neoplasms, Carcinoma, Neoplasms, Stomach Neoplasms

NCT01166542 2014-11-05

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Phase 3 Completed

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Neoplasm Metastasis, Recurrence

NCT00753038 2014-11-04

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Carcinoma

NCT01992341 2014-09-23

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Phase 1 Completed

Carcinoma, Sarcoma

NCT00666692 2012-04-27

A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00034346 2007-12-24

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms